Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Twi Biotechnology Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit, indicating a very specific focus for the company's current prosecution efforts. This consolidated profile suggests that the company is currently prioritizing a single technological path within the biotech field.
The busiest examiner is HUANG, GIGI GEORGIANA, who is assigned 1 pending office action. The outcome of the company's current biotechnology filings is therefore dependent on the specific examination criteria applied by this examiner. To successfully navigate the 1 pending office action, the practitioner must focus on the unique requirements and historical trends associated with this 1 distinct examiner.
The presence of only 1 distinct art unit simplifies the prosecution landscape, as there are no competing procedural demands from other USPTO sections. The 1 pending office action represents the company's entire current workload at the USPTO, making its resolution the most critical factor for the Biotechnology & Pharmaceuticals portfolio at this time. The 1 distinct examiner involved will provide the definitive feedback needed to advance the company's patent applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632770 | 3-HYDROXY-5-PREGNANE-20-ONE DERIVATIVE AND USE THEREOF | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17632770 | 3-HYDROXY-5-PREGNANE-20-ONE DERIVATIVE AND USE THEREOF | HUANG, GIGI GEORGIANA | 1613 | DP | Non-Final OA | — | Pending | Feb 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTwi Biotechnology Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gigi Georgiana Huang has the most, with 1 of Twi Biotechnology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
